Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Dabrafenib and Trametinib in Melanoma
NCT02027961Phase 1Completed
- Sponsor
- MedImmune
- Start
- Dec 2013
- Primary completion
- Apr 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
Phase 1, open-label trial of durvalumab in melanoma (4 cohorts), sponsored by MedImmune. Primary endpoints: Dose Limiting Toxicities, Treatment-emergent Adverse Events and 3 more. Started Dec 2013; status: completed.
02
Drugs
durvalumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02027961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027961.